NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2082.20 10.80 (0.52%)

852.5K NSE+BSE Volume

NSE 28 Nov, 2025 3:31 PM (IST)

95,107

Market Cap

High in industry

Beta 1Year

Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

08 May 2024

2082.20

0.52%

Lupin (HOLD): Stable margins; higher tax weighs on PAT

Hold: Lupin Ltd.

Target

BOB Capital Markets Ltd.

LPC delivered a healthy operational performance in Q4 with largely in-line revenue/PAT; higher tax impacted net profit

Lupin Ltd. has an average target of 2328.00 from 10 brokers.

Lupin Ltd.

07 May 2024

2082.20

0.52%

Mixed Earnings; healthy pipeline of complex products to drive growth

Buy: Lupin Ltd.

Sharekhan

Lupin reported a mix set of earnings where sales were 4% below our estimates at Rs. 4,895 crore. EBITDA was 4% below our estimates at Rs. 997 crore, while adjusted PAT was in-line with our estimate of Rs. 561 crore.

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

24 Apr 2024

2082.20

0.52%

Company Update:Lupin

Buy: Lupin Ltd.

Axis Direct

Niche product approvals and a strong pipeline of new drugs could drive Revenue/PAT CAGR by 10%/19.5% over FY24E-FY26E. We maintain our BUY rating with a Target Price of Rs 1,770/share.

Geojit BNP Paribas upgraded Lupin Ltd. to Buy with a price target of 2225.0 on 25 Nov, 2025.

Lupin Ltd.

15 Apr 2024

2082.20

0.52%

gSpiriva on a healthy growth track, headwinds receding

Buy: Lupin Ltd.

Recommendation Target

Sharekhan

Lupin has recently received approval for a generic version of Oracea (Doxycycline Capsules) in the US market. The company has received approval for 40MG in the US, which is expected to have sales of $128 million in the US market. Lupin has a healthy pipeline of complex generic products in the US market which would aid the company in achieving quarterly US sales of $200-220 million.

Number of FII/FPI investors decreased from 987 to 970 in Sep 2025 qtr

Lupin Ltd.

15 Apr 2024

2082.20

0.52%

Lupin

Buy: Lupin Ltd.

Recommendation Target

Sharekhan

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

13 Feb 2024

2082.20

0.52%

Pick of the Week Lupin Ltd

Buy: Lupin Ltd.

SBI Securities

Lupin Ltd. is trading above all available SMAs

Lupin Ltd.

09 Feb 2024

2082.20

0.52%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

Double-digit growth in India business as the company has already increased MR numbers to 1,000, 4) An uptick in the API business as the API industry is witnessing demand revival. Recommendation: BUY